Sanofi CEO Chris Viehbacher says research departments have been consolidated here to be near universities.
After nine months of denials, rejection, bickering and finally, discussion, French pharmaceutical company Sanofi-Aventis of Paris has signed a deal to buy Genzyme of Cambridge for $20.1 billion plus other milestone payments in the future.
Cambridge-based biotechnology company Genzyme is being bought by French drug maker Sanofi-Aventis for $20.1 billion, ending months of corporate haggling.
Sanofi-Aventis extended its unsolicited $18.5 billion takeover offer for Cambridge biotech company Genzyme Corp. Monday.
The Cambridge biotech company is being pursued by French drug company Sanofi-Aventis. WBZ New England Business Editor Anthony Silva talked with Ken Bredemeier, senior health care reporter at The Deal.